Search
for
Sort by
Research 211–240 of 1000+
- S3886 Concurrent Management of Crohn's Ileitis and Alopecia Universalis With Upadacitinib
- 802 Molecular effect of brepocitinib in hidradenitis suppurativa (HS)
- Baricitinib Demonstrates Rapid Action Within Just 2 Months of Treatment in Severe and Unresponsive Alopecia Areata: A Case Report
- Upadacitinib for the treatment of alopecia areata – A case report
- Advances in the mechanism and new therapies of alopecia areata
- The development of oral hairy leukoplakia during JAK inhibitor baricitinib therapy
- 42736 Safety Assessments in the Multinational Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata
- Citrullination at the Inflammatory Skin Barrier
- JAK inhibitor deuruxolitinib shows encouraging hair re-growth in alopecia areata
- Medical Therapies
- Tofacitinib for the treatment of severe alopecia areata and variants: A retrospective cohort study of 90 patients
- Autophagy Stimulation Improves Erythroid Proliferative Capacity in Models of SF3B1 Mutant MDS
- Tofacitinib citrate alleviates alopecia universalis symptoms in recent case study
- Les Rencontres d’Experts du Psoriasis : des recommandations pour la pratique quotidienne
- Multiomic Characterization of Treatment Response to JAK Inhibition in Patients with APECED
- 0480 Upadacitinib monotherapy for treatment of pyoderma gangrenosum: A case series
- Efficacy and Safety of Switching from Baricitinib to Ritlecitinib in Severe Alopecia Areata
- JAK Inhibitor Baricitinib in the Treatment of Oral Lichen Planus: A Case Report
- Scarring hair follicle destruction is driven by the collapse of EGFR-protected JAK-STAT1-sensitive stem cell immune privilege
- Efficacy and safety of baricitinib in patients with alopecia areata: evidence to date
- Novel TMEM173 Mutation and the Role of Disease Modifying Alleles
- Baricitinib: From Rheumatoid Arthritis to COVID‐19
- STAT5 Activation in the Dermal Papilla Is Important for Hair Follicle Growth Phase Induction
- Treatment of moderate-to-severe alopecia areata in pre-adolescent children with baricitinib
- Successful treatment of concomitant alopecia universalis and Crohn’s disease with upadacitinib: A case report
- Upadacitinib for management of recalcitrant alopecia areata: A retrospective case series
- 54022 Pooled Safety Assessments from the Multinational Phase 3 THRIVE-AA1 and THRIVE-AA2 Trials of Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata
- 44096 Efficacy in Subgroups related to Disease Characteristics in Patients with Alopecia Areata from BRAVE-AA1 and BRAVE-AA2
- 26143 Time to scalp hair, eyebrow, and eyelash improvement in patients with alopecia areata treated with baricitinib in the phase 2 portion of the phase 2/3 BRAVE-AA1 study
- Ivarmacitinib in atopic dermatitis presenting with prurigo nodularis-like lesions and alopecia areata: a case report